Early postmenopausal bone loss in hyperthyroidism

被引:26
作者
Ben-Shlomo, A
Hagag, P
Evans, S
Weiss, M [1 ]
机构
[1] Assaf Harofeh Med Ctr, Endocrine Inst, IL-70300 Zerifin, Israel
[2] Tel Aviv Univ, Sakler Fac Med, IL-69978 Tel Aviv, Israel
[3] Assaf Harofeh Med Ctr, Dept Biochem, IL-70300 Zerifin, Israel
关键词
D O I
10.1016/S0378-5122(00)00179-1
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: To evaluate the effect of hyperthyroidism on bone in relation to the menopausal state. Methods: Fifty-nine hyperthyroid HYPER), 40 hypothyroid (HYPO), and 51 control euthyroid (EUTH) women were studied. Bone mineral density (BMD) was assessed by dual X-rays absorptiometry (DXA) at the lumbar spine, and at the femoral neck. A multi-site QUS device evaluated speed of sound (SOS) at the radius (RAD), tibia (TIB), metatarsus (MTR), and phalanx (PLX). Bone markers used were serum bone specific alkaline phosphatase (BSAP) and urinary deoxypyridinoline (DPD). Results: At all sites, SOS was lower in HYPER than in EUTH (RAD P < 0.05, TIB P < 0.01, MTR P < 0.05, PLX P = 0.01). The low SOS was only noted at the early postmenopausal period. BMD at the femoral neck but not at the lumbar spine was lower in HYPER as compared to EUTH (P < 0.05). Both femoral neck and tibia were the sites with the highest odds ratio for being hyperthyroid (2.3 and 2.04, respectively), There was no correlation between BMD or SOS and FT4, TT3 or duration of hyperthyroidism. BSAP and DPD positively correlated with FT4 and TT3 (P < 0.05), Conclusions: This study suggests that hyperthyroidism affects bone mineralization especially during the early postmenopausal period, and the effect is mainly at the cortical bone. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 40 条
[11]   Identification of metabolic bone disease in patients with endogenous hyperthyroidism: Role of biological markers of bone turnover [J].
Gimeno, EJ ;
MunozTorres, M ;
EscobarJimenez, F ;
Charneco, MQ ;
delCastillo, JDL ;
Olea, N .
CALCIFIED TISSUE INTERNATIONAL, 1997, 61 (05) :370-376
[12]  
GLANT DJ, 1993, CLIN ENDOCRINOL OXF, V39, P529
[13]   Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma [J].
Gorres, G ;
Kaim, A ;
Otte, A ;
Gotze, M ;
MullerBrand, J .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1996, 23 (06) :690-692
[14]   The effect of thyroid hormone on skeletal integrity [J].
Greenspan, SL ;
Greenspan, FS .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (09) :750-758
[15]   THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36
[16]   Does combining the results from multiple bone sites measured by a new quantitative ultrasound device improve discrimination of hip fracture? [J].
Hans, D ;
Srivastav, SK ;
Singal, C ;
Barkmann, R ;
Njeh, CF ;
Kantorovich, E ;
Glüer, CC ;
Genant, HK .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (04) :644-651
[18]   SPINAL BONE-MINERAL CONTENT IN MYXEDEMA AND THYROTOXICOSIS - EFFECTS OF THYROID HORMONE(S) AND ANTI-THYROID TREATMENT [J].
KROLNER, B ;
JORGENSEN, JV ;
NIELSEN, SP .
CLINICAL ENDOCRINOLOGY, 1983, 18 (05) :439-446
[19]   Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: The effect of calcium and calcitonin [J].
Kung, AWC ;
Yeung, SSC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (03) :1232-1236
[20]   THYROXINE SUPPRESSIVE THERAPY DECREASES BONE-MINERAL DENSITY IN POSTMENOPAUSAL WOMEN [J].
KUNG, AWC ;
LORENTZ, T ;
TAM, SCF .
CLINICAL ENDOCRINOLOGY, 1993, 39 (05) :535-540